Noxafil and Neurotoxicity - a phase IV clinical study of FDA data

Summary:

Neurotoxicity is reported as a side effect among people who take Noxafil (posaconazole), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Bactrim, and have Fever.

The phase IV clinical study analyzes which people have Neurotoxicity when taking Noxafil. It is created by eHealthMe based on reports of 5,902 people who have side effects when taking Noxafil from the FDA, and is updated regularly.

What is Noxafil?

Noxafil has active ingredients of posaconazole. eHealthMe is studying from 5,919 Noxafil users. Check the latest studies of Noxafil.

What is Neurotoxicity?

Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system) is found to be associated with 683 drugs and 846 conditions by eHealthMe. Check the latest studies of Neurotoxicity.

On Jul, 12, 2026

5,902 people reported to have side effects when taking Noxafil.
Among them, 24 people (0.41%) have Neurotoxicity.

Among these 24 people:

How long have people been on Noxafil when they have Neurotoxicity? *

What is the gender of people who have Neurotoxicity when taking Noxafil? *

female: 23.81 %
male: 76.19 %

What is the age of people who have Neurotoxicity when taking Noxafil? *

What are other drugs people take besides Noxafil? *

What are other side effects people have besides Neurotoxicity? *

Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 10 people, 41.67%
Hypotension (abnormally low blood pressure): 5 people, 20.83%
Arrhythmias (irregular heartbeat): 5 people, 20.83%
Fever: 5 people, 20.83%
Weakness: 3 people, 12.50%
Abdominal Pain: 3 people, 12.50%
Tremor (trembling or shaking movements in one or more parts of your body): 3 people, 12.50%
Confusion: 3 people, 12.50%
Septic Shock (shock due to blood infection): 3 people, 12.50%
Speech Impairment (Adult) (inability to speak (adult)): 3 people, 12.50%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 3 people, 12.50%
Fever: 3 people, 12.50%
T-Cell Lymphoma Stage Iii (there are cancerous cells in the lymph nodes): 2 people, 8.33%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 8.33%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 8.33%
Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 2 people, 8.33%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 8.33%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 2 people, 8.33%
Gallstones (stone formation by bile component): 1 person, 4.17%
Adverse Drug Reaction: 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Noxafil and have Neurotoxicity?

- Check whether Neurotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Noxafil:

Noxafil (5,919 reports)

Neurotoxicity treatments and more:

Neurotoxicity (16,742 reports)

Browse all side effects of Noxafil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neurotoxicity:

Neurotoxicity (683 drugs)

Browse all the conditions that are associated with Neurotoxicity:

Neurotoxicity (846 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on posaconazole (the active ingredients of Noxafil) and Noxafil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.